Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

nd solid tumors. The IMiDs pipeline is covered by a comprehensive intellectual property estate of U.S. and foreign issued and pending patent applications including composition-of- matter and use patents.

About Multiple Myeloma

Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease remains unknown.

About RevAssist(R)

FOR FURTHER INFORMATION ABOUT REVLIMID AND RevAssist, A RESTRICTED DISTRIBUTION PROGRAM USED IN THE UNITED STATES, YOU MAY GO TO THE INTERNET AT www.REVLIMID.com OR BY CALLING THE MANUFACTURER'S TOLL FREE NUMBER 1-888- 4CELGENE. RevAssist is a proprietary risk-management restrictive distribution program, tailored specifically for REVLIMID patients, to prevent the potential for human birth defects and ensure prompt and convenient access to REVLIMID through contracted pharmacies.

About ECOG

The Eastern Cooperative Oncology Group (ECOG) was established in 1955 as one of the first cooperative groups launched to perform multi-center cancer clinical trials. A cooperative group is a large network of researchers, physicians, and health care professionals at public and private institutions across the country who are members of the group. Funded primarily by the National Cancer Institute (NCI), ECOG has evolved from a five member consortium
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/22/2014)... , Aug. 22, 2014 Today, ... that modify the religious "accommodation" but still require ... that have an abortifacient effect, including Plan B ... after pill"). The Obama Administration also announced that ... closely held, for-profit corporations. The regulations ...
(Date:8/22/2014)... Aug. 22, 2014  Dr. Mark Rasak , ... Diamond Lifetime Achievement Award in the field of Medicine ... Cardiovascular Clinical Associates. Dr. Rasak has over ... major aspects of the business; overseeing the daily operations; ... coronary intervention. In addition, he is an honored Fellow ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research ... shows that a therapy being developed by Hera Therapeutics Inc. ... cause 70 percent of all cervical cancer. When ... replication of HPV-16, HPV-18 and HPV-11 cells, according to ... Ph.D., who presented the findings at the Seattle ...
Breaking Medicine Technology:Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... At its regularly scheduled meeting on September 14, ... (the "Company" or "AMPAC") (Nasdaq: APFC ) ... that shareholders at the next Annual Meeting amend AMPAC,s ... for director election with a simple majority vote requirement. ...
... U.S. Food and Drug Administration (FDA), working in close ... announced that Forest Pharmaceuticals, Inc. entered into a plea ... actions including distribution of an unapproved new drug, distribution ... inspection. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:American Pacific Adopts Corporate Governance Changes 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
(Date:8/23/2014)... 23, 2014 Legal Insider Bot ... by Greg Marks has been generating a buzz of ... The commotion surrounding the new product has drawn the ... , “In recent years the market has ... commonly referred to as robots or ‘bots,'” reports Hendricks. ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... August 23, 2014 Professional kitchen employees, ... study aid in preparing for Food Safety Certification exams ... by Dynamic Path. , Dynamic Path announced the ... includes more than 200 review questions for culinary industry ... designed to cover requirements of the ServSafe® Food Safety ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Young adults in Athens, ... doing drugs should pick up the phone and call the new ... teen drug addict . , Troubled Teen Athens is a ... ready to finally take the necessary steps to end substance abuse ... are quick to go to friends or peers when really they ...
(Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... of the population but account for nearly 20 percent ... major risk factor for // suicide in the elderly. ... thoughts in depressed elderly patients. ,Researchers from ... 600 elderly patients with depression. Some patients were assigned ...
... skin’s worst enemies, but now some dermatologists are taking cues from sunlight ... phototherapy. ,Standing in front of a UV light is ... from a disease called morphea , it can affect any area of ... joints, also known as localized scleroderma. She says: “I had a bunch ...
... can be a significant predictor of breast cancer risk for ... ,In 1992, researchers sampled nearly 62,000 women, ages ... age 18 and their current weight. Since then, the women ... in addition to any diagnosis of cancer. Research shows ...
... Around 165,000 cases of lung cancer are diagnosed in ... to 25 percent are classified // as small cell ... and the disease frequently travels to the brain and ... cancer, for example, ranges up to 80 percent. Whether ...
... a new drug is showing promising results.For the past ... recombinant immunotoxins. An immunotoxin is bioengineered and consists of ... antibodies that are commonly used to fight leukemia. One ... a phase II study. ,Researchers say in a ...
... A recent study has shown that a chemotherapy regimen ... prednisone is effective in the treatment of hormone-refractory prostate ... to symptomatic patients earlier in their disease. ... study of this treatment regimen is planned. From a ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Sterile cordless eraser tips, packsize is 10/box....
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Medicine Products: